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Abstract The high throughput screening of a library of over 87,000 drug-like compounds against the African Sleeping
Sickness parasite resulted in the discovery of hits with a wide range of molecular diversity. We report here the medicinal
chemistry development of one such hit, a tetrahydroisoquinoline disulfonamide, with the synthesis and testing of 26
derivatives against the trypanosome subspecies. Activities in the 2-4 µM range were revealed with a selectivity index suitable
to further development.
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Trypanosoma brucei gambiense and T. brucei rhodesiense are
the causative agents of human African trypanosomiasis (HAT), also
known as sleeping sickness. T. b. rhodesiense is found in Eastern
and Southern Africa, whereas T. b. gambiense occurs in Western
and Central Africa and is responsible for over 90% of all reported
cases of infection.1 This disease threatens about 70 million people
living in sub-Saharan Africa and causes an estimated 25,000 deaths
per year.2,3 It has a major impact on the affected nations causing
suffering and poverty and if left untreated, the disease is usually
fatal.4 A lack of full-scale screening programs and poor diagnostic
tools leads to an under-reporting of cases, which is likely to be at
least threefold higher than the measured value.5
Both subspecies are transmitted by the bite of the infected tsetse
fly. T. b. gambiense HAT is primarily a chronic disease and it can
be many months to years before patients succumb to the disease. In
contrast, T. b. rhodesiense HAT is acute, with death occurring
within months of infection. After the bite, the parasites start to
multiply in the blood; that is, phase I. During this phase, the
parasite lives within the bloodstream and subsequently migrates to
other areas of the human body, such as the lymph nodes and spleen,
causing febrile illness with symptoms similar to those caused by
malaria (rash, fever, shaking chills, body aches, and general
fatigue). If phase I is left untreated, the parasites penetrate the
blood brain barrier and invade the central nervous system (CNS)
(phase II) causing neurological symptoms including progressive
mental deterioration, sleep disturbances, long lasting coma and
finally death if not treated.6
Unfortunately, vaccines are not available and therefore, the main
line of defense against the parasite is chemotherapeutics. The
treatment options are limited with only four registered drugs
available. Suramin and pentamidine are effective against early
stage infections while melarsoprol (contains arsenic) and
eflornithine are used to treat late-stage disease (Figure 1).7,8 These

drugs were developed approximately 30 years ago and suffer high
toxicity, lack of efficacy and emerging resistance is a concern.
Melarsoprol is the most toxic, causing a reactive encephalopathy in
5−10% of treated patients, with a 1−5% mortality rate.9

Figure 1. Older generation African sleeping sickness drugs.

Recently, there has been some progress in the treatment of
HAT10 with a nifurtimox–eflornithine (Figure 1) combination
(NECT) therapy developed which is as effective as eflornithine
mono-therapy but was easier and cheaper to administer.11,12
However, NECT is not ideal due to the parental mode of
administration, the need to hospitalize patients during treatment and
the possible development of resistance. 13,14
Increased research and investment into HAT chemotherapy has
resulted in the identification of numerous trypanocidal compounds,
a number of which have entered or are in clinical development. The
diminazene, pafuramidine15 (Figure 2) was the first oral drug to

enter clinical development for early stage HAT in 2005. However,
the observation of severe hepatic toxicity and renal insufficiency
during a retrospective phase I trial in 2008 lead to the compound
being abandoned. In 2009, a second orally available drug,
fexinidazole16 (Figure 2), entered phase I clinical trials for HAT.
The drug is effective against both stages of the disease and
subsequently progressed to phase II/III clinical development in
2012.

by comparing the IC50 in the T. b. brucei assay and the highest dose
at which there was no activity (<50%) in the HEK 293 assay.

More recently, the novel boron-containing molecule (SCYx7158) (Figure 2) emerged as an orally active drug candidate, with
promising activity against both acute and CNS stage infections. The
compound successfully completed preclinical studies in 2011 and
entered phase I clinical trials in 2012.17 The mechanism by which
the boronate acts as a trypanocidal agent is still unknown. Overall,
present treatment options for HAT are limited and the high attrition
rates in drug discovery means that new therapeutics with acceptable
efficacies and safety profiles are urgently needed.18

Figure 3. Lead compound (WEHI 1203255), IC50= 1.3 µM.

The strategy for the synthesis of sulfonamide analogues is
summarised
in
Scheme
1,
and
started
from
7nitrotetrahydroquinoline which was sulfonated using the
appropriate sulfonyl chloride in pyridine at room temperature. The
nitro group was reduced, initially using acetic acid in ethanol in the
presence of tin with sonication,21 however, under these conditions,
yields were between 50-60%. The use of Raney nickel in methanol
in presence of hydrazine hydrate as a source of hydrogen reliably
gave the aniline derivatives in gram quantities in 80-90% yields.
The amino group was then reacted with the different sulfonyl
chlorides in pyridine at room temperature (scheme 1), giving in 7080% yield, the final analogues. HPLC analysis of these bissulfonamides showed a purity range > 95% for all the synthesized
derivatives. This facile three step synthetic strategy enabled us to
access 26 separate derivatives in a short timeframe, reliable yields
as well and at reasonable cost.

Figure 2. New generation of potential African sleeping sickness
treatments.

High throughput screening (HTS) is one approach that can be
used to identify new lead compounds for such neglected diseases.
Therefore, the HTS library of 87,926 compounds (WEHI 2003)19
was tested against the non-human infective trypanosome
subspecies, Trypanosoma brucei brucei and against a mammalian
cell line HEK293, to determine a selectivity index (SI) for each
compound. Although T. b. brucei is non-human infective it is
frequently used in HAT drug discovery campaigns and lead
optimization programs as a model for the human infective
subspecies (T. b. gambiense and T. b. rhodesiense) which are more
difficult to maintain and culture in-vitro. Cluster analysis,
considering chemical alerts such as toxicophores, the likelihood of
CNS penetration, and drug-like structural features yielded a subset
of twelve compounds as promising medicinal chemistry starting
points for drug development.
This article discusses the synthesis and anti-trypanocidal activity
of new analogues for the bis-sulfonamide hit, WEHI-1203255
(Figure 3), which showed an IC50 value of 1.3 µM with a SI of >32.
This compound has excellent physiochemical properties, good
calculated aqueous solubility of 100 µM, an acceptable polar
surface area of 84 Å2, and an acceptable CLogP value20 of 2.5. The
analogues were synthesized and tested for their ability to inhibit the
growth of T. b. brucei limiting the changes to the two sulfonamide
moieties to study the preliminary structure activity relationships.
The cytotoxicity profiles of the compounds were evaluated using
HEK293 cell line and SI was estimated for each analogue. The SI
of the compounds was determined where possible by directly
comparing the IC50 values from the T. b. brucei and HEK 293
assay. If this was not possible, an estimated SI value was calculated

Scheme 1. Reagents and conditions: (a) Dry pyridine, R1SO2Cl,
rt, 24 h; (b) Methanol, NH2NH2.H2O, Raney Nickel, reflux, 6-8
h; (c) Dry pyridine, R2SO2Cl, 0 °C to rt, 4-6 h.
The results for the testing against T. b. brucei, the calculated
ClogP and the SI are listed in Table 1. The initial activity was
determined by screening at 1 µM and 10 µM and derivatives
showing > 80% activity at 10 µM and >50% activity at 1 µM were
then tested to obtain the IC50 values. The first series of derivatives
examined the changes in the aromatic sulfonyl moiety where the
lead compound 10 has a fluorine atom in the ortho position. This
lead compound was also resynthesised and tested with IC50/SI= 1.3
µM/>32, confirming the activity results from the initial HTS.
Changing the ortho-fluoro substituent to the para (11) and meta
(12) positions, did not improve activity where the IC50/SI profile
was 7.8 µM/>10 for both derivatives, indicating a slightly
decreased trypanocidal activity and increased toxicity compared to
10. Increasing the number of the fluorine atoms had a negative
effect on the activity, where the addition of a second fluoro
substituent into the adjacent ortho position (13) resulted in a
decreased activity (82% activity at 10 µM) as did the presence of
five fluoro substituents (14, 94% activity at 10 µM). This implied
the importance of the mono-fluoro atom only in the ortho position,
with no advantages with the presence of the extra fluorine atoms.

Table 1 R1, R2, molecular weight, ClogP, IC50 and
1

R

2

R

Mwt

ClogP*

IC50 (µM)

Selectivity Index for compounds 10-35.

S.I.

16.6
24

10

Et

398.5

2.5±0.8

1.3±0.6

32±3.1

11

Et

398.5

3.0±0.8

7.8±2.7

11.8±4.1

Pr

470.6

4.9±0.8

±

5.7 ± 2.8
8.2

24.3
25

Pr

412.5

3.0±0.8

±

3.5 ±0.8
5.3

12

Et

398.5

3.1±0.8

7.8±2.2

11.2±2.5

13

Et

416.5

2.3±0.9

82% @ 10 µM

14

Et

470.4

3.4±1.1

94% @ 10 µM

15

Et

477.4

3.5±0.9

9.9±3.3

9.0±2.3

16

Et

386.5

2.3±0.8

4.0±0.6

20.8±2.9

17

Et

465.4

3.5±0.9

11.2±2.6

7.7±1.6

18

Et

421.0

3.3±0.9

13.1±4.3

6.9±2.2

19

Et

394.5

3.1±0.8

3.4±0.9

20

Et

332.4

1.6±0.8

14% @ 10 µM

21

Et

386.4

2.8±0.9

18% @ 10 µM

Et

1.84
22

Pr

408.5

436.6

400.5

2.8±0.8

< 10% @ 10 µM

27

Pr

408.5

3.7±0.8

11% @ 10 µM

28

Pr

408.5

3.7±0.8

<10% @ 10 µM

29

Pr

422.6

4.1±0.8

9 ± 4.3

30

Pr

422.6

4.1±0.8

<10% @ 10 µM

31

Pr

464.6

5.5±0.8

7.9 ±3.2

32

440.6

2.3±0.8

35% 10 µM

33

448.6

3.1±0.8

3.1±0.9

2.5±0.5

34

448.6

3.1±0.8

7.6±2.6

1.7±0.5

35

456.6

3.9±0.8

3.9±0.9

1.8±0.4

10.4 ± 5

11.4±4.7

±

29

±

3.7±0.8

1.71
Pr

Pr

25.8±2.9

0.09

23

26

25.4
±
8.9 ± 1.5

4.5±0.8
0.53

*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto,
Canada), S.I. = selectivity index.

The fluorine atom is the smallest halogen size, therefore, it
was interesting to test the presence of other halogen atoms.
The addition of a bromo substituent at the para position
(compound 15) resulted in increased toxicity and did not
improve the activity (IC50/SI= 9.9 µM/>8).

Replacing the benzene moiety with its bioisostere
thiophene22,23 (16) resulted in a similar activity (IC50/SI= 4.0
µM/>20) compared to the lead 10. The same activity profile of
10 and the simpler 16 might be attributed to the lipophilic
nature of the thiophene ring in 16 that might have the same
effect as the fluorine atom in 10. The addition of another
halogen to this thiophene (Br, 17) showed a decreased

trypanocidal activity (IC50/SI= 11.2 µM/>7), and a concurrent
reduction in the SI value compared to the unsubstituted
thiophene analogue 16. Replacement of the bulky bromo
substituent in 17 by a chloro substituent (18) was also not
tolerated, with a similar decrease in activity (IC50/SI= 13.1
µM/>6). The activity of 18 was 3 fold less than that of 16 but
similar to that of 17.
Replacing the aromatic moiety with aliphatic chains as in
compounds 20 and 21 completely abolished the activity which
indicates the importance of the aromatic ring in that position
for the trypanocidal activity. The π system of the aromatic ring
may be involved in the interaction site, whereas with aliphatic
side chains, such interactions don’t exist. Interestingly, the
introduction of a small hydrophobe such as a methyl group on
the para position on the phenyl ring of the aromatic sulfonyl
moiety (compound 19) made little difference to the activity
(IC50/SI= 3.4 µM/>24) compared to 10. As the mode of action
and the target of the compounds are not yet known, the role of
this methyl group cannot be assured, however, it might be
involved in a hydrophobic interaction within the target site.
The extension of the ethyl side chain of the other sulfonyl
group (second changeable moiety) to a propyl group, as in
compound 22, was also tolerated (IC50/SI= 1.84 µM/>29) with
no significant difference in the activity compared to 19.
However, in the case of compound 26, the extra length of this
substituent was not tolerated. When the p-tolyl group of 22
was replaced by a thiophene ring (compound 26), the activity
was completely abolished due to the propyl group compared to
16 (with an ethyl side chain).
The para position of the methyl hydrophobe in 22 was
important for activity as can be indicated by the inactivity of
compounds 27 (ortho position) and 28 (meta position). The
relatively good activity of 29 and 31 is moderated by a poor SI
when compared to 10 or 22. The inactivity of 30 (no p-methyl
group) also gives indications about the importance of the para
position. Figure 4 shows the SAR for this series of bissulfonamides.
Addition of the hydrophobic methyl groups on either the
ethyl side chain or on the aromatic sulfonyl moieties seemed to
act as a tuner for the activity. Compound 26 was completely
inactive whereas compound 25 showed similar activity and
selectivity (IC50/SI= 3.5 µM/>24) compared to the lead 10.
Increasing the bulkiness of compound 22 to 23 (replacing the
small methyl hydrophobe with the more bulky isopropyl
group) resulted in a similar activity profile but increased
toxicity (IC50/SI= 1.71 µM/>8). Further increases in the
bulkiness by replacing the isopropyl in 23 by a phenyl ring
(24) decreased the activity (IC50/SI= 5.7 µM/>16) by 3 fold
compared to 23. This difference could be attributed to a size
effect. This also confirms that the π system of the aromatic
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ring (directly attached to the sulfonamide group) might be
involved in the activity.
When the aliphatic sulfonyl side chain (sulfonyl group
attached to the tetrahydroquinoline N) was replaced with
aromatic ring, the activity was either completely abolished as
in case of compound 32 or toxicity was increased as in
compounds 33-35. Interestingly, compound 33 carrying the
para methyl group was the best in this series (IC50/SI= 3.1
µM/>2), confirming the importance of the para position on
this aromatic moiety. The aliphatic sulfonyl groups directly
attached to the tetrahydroquinoline ring is important for
activity rather than an aromatic replacement.
An initial structure-activity relationships (SAR) model can
be generated from this information (Figure 4). Treating the
tetrahydroisoquinoline unit as a scaffold, toxicity is minimized
if the sulfonamide (blue) is aliphatic with the hydrophobicity
tolerated up to 3 methylene units. Larger moieties reduce the
activity. In contrast, the 2nd sulfonamide unit (red) must be
aromatic, indicating that the π‐electrons are likely to be
significant. Aliphatic substituents abolish activity.

Figure 4. Structure-activity relationships for the bis-sulfonamides

The activity is maximized when this aromatic unit is
substituted in the para position. The substituent is best as a
small hydrophobic unit with a positive inductive effect.
This study revealed a new structural class of T. brucei
inhibitors with a good selectivity index, suitable for further
investigations. Close adherence to drug-like properties
throughout the study kept the mwt of synthesized derivatives
low and ClogP were used as a guide to pharmacokinetic
properties to maintain. Initial SAR studies confirm the initial
hit compound and enabled basic design principles to be
observed. Further optimization of this sulfonamide series is
possible, in particular the para position of the terminal aryl
sulfonamide group, and further studies in this direction will be
forthcoming. Therefore, the discovery of the bis-sulfonamides
as a novel class of antiparasitic agents offers a new medicinal
chemistry opportunity for targeting T. brucei spp.

SUPPORTING INFORMATION AVAILABLE Synthetic
and biological experimental procedures, selected dose
response curves (active compounds), full characterization of
the synthesized compounds, and biological assay protocol data
are available.
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